Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms

European Journal of Immunology

Volumn 28, Issue 1, 1998, Pages 305-316

  Fujita, Hiroshi ^a,b   Senju, Satoru ^a   Yokomizo, Hiroshi ^a,b   Saya, Hideyuki ^b   Ogawa, Michio ^b   Matsushita, Sho ^a   Nishimura, Yasuharu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Antigen presentation; HLA; p53 tumor suppressor gene; T cell; Tumor immunity

Indexed keywords

CD4 ANTIGEN; HLA ANTIGEN CLASS 2; MUTANT PROTEIN; PEPTIDE; PROTEIN P53; RECOMBINANT PROTEIN;

ARTICLE; B LYMPHOBLAST; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PRIORITY JOURNAL; PROTEIN DENATURATION; T LYMPHOCYTE;

ADULT; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES; GENES, P53; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOKINES; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; PROTEIN DENATURATION; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECOMBINANT FUSION PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031984762     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-4141(199801)28:01<305::AID-IMMU305>3.0.CO;2-3     Document Type: Article

References (61)

1. Boon, T. and van der Bruggen, P., Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 1996. 183: 725-729.
2. Houghton, A. N., Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 1994. 180: 1-4.
3. Nanda, N. K. and Sercarz, E. F., Induction of anti-self-immunity to cure cancer. Cell 1995. 82: 13-17.
4. Lanzavecchia, A., How can cryptic epitopes trigger autoimmunity? J. Exp. Med. 1995. 181: 1945-1948.
5. Ozdemirli, M., el-Khatib, M., Bastiani, L., Akdeniz, H., Kuchroo, V. and Ju, S. T., The cytotoxic process of CD4 Th1 clones. J. Immunol. 1992. 149: 1889-1895.
6. - T cells and is restricted to the DR region of the MHC complex. J. Immunol. 1988. 140: 3610-3616.
7. Chicz, R. M., Urban, R. G., Gorga, J. C., Vignali, D. A., Lane, W. S. and Strominger, J. L., Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 1993. 178: 27-47.
8. Cabrera, T., Ruiz-Cabello, F. and Garrido, F., Biological implication of HLA-DR expression in tumours. Scand. J. Immunol. 1995. 41: 398-406.
9. + T cells in cancer immunotherapy. Curr. Opin. Immunol. 1994. 6: 741-745.
10. + T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. Eur. J. Immunol. 1995. 25: 2588-2597.
11. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int. J. Cancer 1994. 58: 69-79.
12. + cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients. Int. J. Cancer 1995. 60: 802-807.
13. Bargou, R. C., Daniel, P. T., Mapara, M. Y., Bommert, K., Wagener, C., Kallinich, B., Royer, H. D. and Dorken, B., Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int. J. Cancer 1995. 60: 854-859.
14. Tamura, T., Aoyama, N., Saya, H., Futami, S., Miyamoto, M., Koh, T., Ariyasu, T., Tachi, M., Kasuga, M. and Takahashi, R., Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene 1995. 11: 1939-1946.
15. Weller, M., Malipiero, U., Aguzzi, A., Reed, J. C. and Fontana, A., Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest. 1995. 6: 2633-2643.
16. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C., p53 mutations in human cancers. Science 1991. 253: 49-53.
17. Scheffner, M., Huibregtse, J. M., Vierstra, R. D. and Howley, P. M., The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993. 75: 495-505.
18. Lane, D. P., Cancer p53, guardian of the genome. Nature 1992. 358: 15-16.
19. Schlichtholz, B., Legros, Y., Gillet, D., Gaillard, C., Marty, M., Lane, D., Calvo, F. and Soussi, T., The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 1992. 52: 6380-6384.
20. Lubin, R., Schlichtholz, B., Bengoufa, D., Zalcman, G., Tredaniel, J., Hirsch, A., de Fromentel, C. C., Preudhomme, C., Fenaux, P., Fournier, G., Bressac, B. and Soussi, T., Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res. 1993. 53: 5872-5876.
21. Labrecque, S., Naor, N., Thomson, D. and Matlashewski, G., Analysis of the anti-p53 antibody response in cancer patients. Cancer Res. 1993. 53: 3468-3471.
22. Houbiers, J. G., van der Burg, S. H., van de Watering, L. M., Tollenaar, R. A., Brand, A., van de Velde, C. J. and Melief, C. J., Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br. J. Cancer 1995. 72: 637-641.
23. Lubin, R., Zalcman, G., Bouchet, L., Tredanel, J., Legros, Y., Cazals, D., Hirsch, A. and Soussi, T., Serum p53 antibodies as early markers of lung cancer. Nature Med. 1995. 1: 701-702.
24. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 1996. 183: 1965-1971.
25. Yokomizo, H., Matsushita, S., Fujisao, S., Murakami, S., Fujita, H., Shirouzu, M., Yokoyama, S., Ogawa, M. and Nishimura, Y., Augmentation of Immune Response by an Analog of the Antigenic peptide in a Human T-cell Clone Recognizing Mutated Ras-derived Peptides. Hum. Immunol. 1997. 52: 22-32.
26. Matlashewski, G., Lamb, P., Pim, D., Peacock, J., Crawford, L. and Benchimol, S., Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J. 1984. 3: 3257-3262.
27. Zakut-Houri, R., Bienz-Tadmor, B., Givol, D. and Oren, M., Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J. 1985. 4: 1251-1255.
28. Aoyama, N., Nagase, T., Sawazaki, T., Mizuguchi, G., Nakagoshi, H., Fujisawa, J. I., Yoshida, M. and Ishii, S., Overlap of the p53-responsive element and cAMP-responsive element in the enhancer of human T-cell leukemia virus type I. Proc. Natl. Acad. Sci. USA 1992. 89: 5403-5407.
29. Matozaki, T., Sakamoto, C., Suzuki, T., Matsuda, K., Uchida, T., Nakano, O., Wada, K., Nishisaki, H., Konda, Y., Nagao, M. and Kasuga, M., p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells. Cancer Res. 1992. 52: 4335-4341.
30. Inui, S., Kuwahara, K., Mizutani, J., Maeda, K., Kawai, T., Nakayasu, H. and Sakaguchi, N., Molecular cloning of a cDNA clone encoding a phosphoprotein component related to the lg receptor-mediated signal transduction. J. Immunol. 1995. 154: 2714-2723.
31. Smith, D. B. and Johnson, K. S., Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 1988. 67: 31-40.
32. Sone, T., Tsukamoto, K., Hirayama, K., Nishimura, Y., Takenouchi, T., Aizawa, M. and Sasazuki, T., Two distinct class II molecules encoded by the genes within HLA-DR subregion of HLA-Dw2 and Dw12 can act as stimulating and rectriction molecules. J. Immunol. 1985. 135: 1288-1298.
33. Hirayama, K., Nishimura, Y., Tsukamoto, K. and Sasazuki, T., Functional and molecular analysis of three distinct HLA-DR4 beta-chains responsible for the MLR between HLA-Dw4, Dw15, and DKT2. J. Immunol. 1986. 137: 924-933.
34. Kasahara, M., Takenouchi, T., Ogasawara, K., Ikeda, H., Okuyama, T., Ishikawa, N., Moriuchi, J., Wakisaka, A., Kikuchi, Y., Aizawa, M., Kaneko, T., Kashiwagi, N., Nishimura, Y. and Sasazuki, T., Serologic dissection of HLA-D specificities by the use of monoclonal antibodies. Immunogenetics 1983. 17: 485-495.
35. Ishikawa, N., Kojima, H., Nakayama, T., Kunikane, H., Hawkin, S., Fukasawa, Y., Ikeda, H., Ogasawara, K., Kasahara, M., Tajima, Y., Kakuta, Y., Wakisaka, A. and Aizawa, M., Detection of a novel HLA-DQ specificity: serological and immunochemical analyses by a monoclonal antibody. Immunogenetics 1987. 26: 143-149.
36. Hirata, R. and Maeda, H., The structural polymorphism of HLA-DR nad -DR52b chains investigated by one-dimensional isoelectric focusing and immunoblotting. In Tsuji, K., Aizawa, M. and Sasazuki, T. (Eds.). HLA 1991 Proceedings of Eleventh International Histocompatibility workshop and conferance, Vol 1. Oxford University Press, London 1992, pp 853-858.
37. Nishimura, Y., Thorsby, E., Ronningman, K., Nelson, L., Hansen, J., Bias, W., Fauchet, R., Dawkins, R., Tiilikainen, A., Salvaneschi, L., Martinetti, M., Cuccia, M., Vaughan, R., Hall, M., Boehm, B., Juji, T., Ohno, S., Farid, N., Bodmer, J., Skamene, E., Marsh, D., Svejgaard, A., Thomson, A. and Sasazuki, T., In Tsuji, K., Aizawa, M. and Sasazuki, T. (Eds.) HLA, 1991. General organization and overview of the disease component. Oxford University Press, London 1991, pp 693-700.
38. Matsushita, S., Takahashi, K., Motoki, M., Komoriya, K., Ikagawa, S. and Nishimura, Y., Allele specificity of structural requirement for peptides bound to HLA-DRB1*0405 and -DRB1*0406 complexes: implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome. J. Exp. Med. 1994. 180: 873-883.
39. Bodmer, J. G., Marsh, S. G., Albert, E. D., Bodmer, W. F., Dupont, B., Erlich, H. A., Mach, B., Mayr, W. R., Parham, P., Sasazuki, T. and Strominger, J. L., Nomenclature for factors of the HLA system, 1994. Hum. Immunol. 1994. 41: 1-20.
40. Klohe, E. P., Watts, R., Bahl, M., Alber, C., Yu, W. Y., Anderson, R., Silver, J., Gregersen, P. K. and Karr, R. W., Analysis of the molecular specificities of anti-class II monoclonal antibodies by using L cell transfectants expressing HLA class II molecules. J. Immunol. 1988. 141: 2158-2164.
41. Ikagawa, S., Matsushita, S., Chen, Y. Z., Ishikawa, T. and Nishimura, Y., Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j 1)-derived peptide induced alterations in human T cell responses and T cell receptor antagonism. J. Allergy Clin. Immunol. 1996. 97: 53-64.
42. Tatsue, M. and Donald, P., Exogeneously Provided peptides Fail to Complex with Intracellular Class II Molecules for Presentation by Antigen-Presenting Cells. J. Immunol. 1997. 158: 3155-3163.
43. Kayagaki, N., Kawasaki, A., Ebata, T., Ohmoto, H., Ikeda, S., Inoue, S., Yoshino, K., Okumura, K. and Yagita, H., Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 1995. 182: 1777-1783.
44. Houbiers, J. G., Nijman, H. W., van der Burg, S. H., Drijfhout, J. W., Kenemans, P., van de Velde, C. J., Brand, A., Momburg, F., Kast, W. M. and Melief, C. J., In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 1993. 23: 2072-2077.
45. Noguchi, Y., Richards, E. C., Chen, Y. T. and Old, L. J., Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 1995. 92: 2219-2223.
46. Mayordomo, J. I., Loftus, D. J., Sakamoto, H., De Cesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E. and DeLeo, A. B., Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 1996. 183: 1357-1365.
47. Gnjatic, S., Bressac-de Paillerets, B., Guillet, J. G. and Choppin, J., Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. Eur. J. Immunol. 1995. 25: 1638-1642.
48. Zeh, H., Jr., Leder, G. H., Lotze, M. T., Salter, R. D., Tector, M., Stuber, G., Modrow, S. and Storkus, W. J., Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum. Immunol. 1994. 39: 79-86.
49. Nijman, H. W., Houbiers, J. G., van der Burg, S. H., Vierboom, M. P., Kenemans, P., Kast, W. M. and Melief, C. J., Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J. Immunother. 1993. 14: 121-126.
50. Nijman, H. W., Van der Burg, S. H., Vierboom, M. P., Houbiers, J. G., Kast, M. W. and Melief, C. J., p53, a potential target for tumor-directed T cells, Immunol. Lett. 1994. 40: 171-178.
51. Stuber, G., Leder, G. H., Storkus, W. T., Lotze, M. T., Modrow, S., Szekely, L., Wolf, H., Klein, E., Karre, K. and Klein, G., Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur. J. Immunol. 1994. 24: 765-768.
52. Tilkin, A. F., Lubin, R., Soussi, T., Lazar, V., Janin, N., Mathieu, M. C., Lefrere, I., Carlu, C., Roy, M., Kayibanda, M., Bellet, D., Guillet, J. G. and Pallerets, B. B., Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur. J. Immunol. 1995. 25: 1765-1769.
53. Sercarz, E. E., Lehmann, P. V., Ametani, A., Benichou, G., Miller, A. and Moudgil, K., Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 1993. 11: 729-766.
54. Moudgil, K. D. and Sercarz, E. E., The T cell repertoire against cryptic self determinants and its involvement in autoimmunity and cancer. Clin. Immunol. Immunopathol. 1994. 73: 283-289.
55. Pavletich, N. P., Chambers, K. A. and Pabo, C. O., The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 1993. 7: 2556-2564.
56. Bargonetti, J., Manfredi, J. J., Chen, X., Marshak, D. R. and Prives, C., A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 1993. 7: 2565-2574.
57. Cho, Y., Gorina, S., Jeffrey, P. D. and Pavletich, N. P., Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994. 265: 346-355.
58. Medcalf, E. A. and Milner, J., Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation. Oncogene 1993. 8: 2847-2851.
59. Milner, J., DNA damage, p53 and anticancer therapies. Nature Med. 1995. 1: 879-880.
60. Cibotti, R., Kanellopoulos, J. M., Cabaniols, J. P., Halle-Panenko, O., Kosmatopoulos, K., Sercarz, E. E. and Kourilsky, P., Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc. Natl. Acad. Sci. USA 1992. 89: 416-420.
61. Disis, M. L., Gralow, J. R., Bernhard, H., Hand, S. L., Rubin, W. D. and Cheever, M. A., Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/ neu, oncogenic self-protein. J. Immunol. 1996. 156: 3151-3158.